ES2872674B2 - Metodo para la deteccion y cuantificacion de fosfomicina y de sus impurezas y/o productos de degradacion - Google Patents
Metodo para la deteccion y cuantificacion de fosfomicina y de sus impurezas y/o productos de degradacion Download PDFInfo
- Publication number
- ES2872674B2 ES2872674B2 ES202190053A ES202190053A ES2872674B2 ES 2872674 B2 ES2872674 B2 ES 2872674B2 ES 202190053 A ES202190053 A ES 202190053A ES 202190053 A ES202190053 A ES 202190053A ES 2872674 B2 ES2872674 B2 ES 2872674B2
- Authority
- ES
- Spain
- Prior art keywords
- fosfomycin
- impurities
- sample
- pharmaceutically acceptable
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 title claims description 171
- 229960000308 fosfomycin Drugs 0.000 title claims description 171
- 239000012535 impurity Substances 0.000 title claims description 109
- 238000000034 method Methods 0.000 title claims description 57
- 239000007857 degradation product Substances 0.000 title claims description 29
- 238000001514 detection method Methods 0.000 title claims description 18
- 238000011002 quantification Methods 0.000 title claims description 13
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 83
- 239000001384 succinic acid Substances 0.000 claims description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 36
- QZIQJIKUVJMTDG-JSTPYPERSA-L disodium;[(2r,3s)-3-methyloxiran-2-yl]-dioxido-oxo-$l^{5}-phosphane Chemical compound [Na+].[Na+].C[C@@H]1O[C@@H]1P([O-])([O-])=O QZIQJIKUVJMTDG-JSTPYPERSA-L 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 23
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 19
- 238000010828 elution Methods 0.000 claims description 16
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 12
- 239000005695 Ammonium acetate Substances 0.000 claims description 12
- 235000019257 ammonium acetate Nutrition 0.000 claims description 12
- 229940043376 ammonium acetate Drugs 0.000 claims description 12
- 238000004949 mass spectrometry Methods 0.000 claims description 12
- 238000004811 liquid chromatography Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000000443 aerosol Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 230000005526 G1 to G0 transition Effects 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000000523 sample Substances 0.000 description 67
- 239000008186 active pharmaceutical agent Substances 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 239000000539 dimer Substances 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000003085 diluting agent Substances 0.000 description 20
- 230000014759 maintenance of location Effects 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 239000013638 trimer Substances 0.000 description 12
- 239000012086 standard solution Substances 0.000 description 10
- QGQXAMBOYWULFX-LZWSPWQCSA-N 2-morpholin-4-ylethyl (e)-6-(4,6-dihydroxy-7-methyl-3-oxo-1h-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound OC=1C=2C(=O)OCC=2C(C)=C(O)C=1C\C=C(/C)CCC(=O)OCCN1CCOCC1 QGQXAMBOYWULFX-LZWSPWQCSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 229940127557 pharmaceutical product Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000012062 charged aerosol detection Methods 0.000 description 3
- 150000001793 charged compounds Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 238000005464 sample preparation method Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 108010022337 Leucine Enkephalin Proteins 0.000 description 2
- 239000004696 Poly ether ether ketone Substances 0.000 description 2
- 239000004280 Sodium formate Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000012482 calibration solution Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000001360 collision-induced dissociation Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920002530 polyetherether ketone Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 235000019254 sodium formate Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- MXMXXUIOCREOTJ-UHFFFAOYSA-N 1,2-dihydroxypropylphosphonic acid Chemical compound CC(O)C(O)P(O)(O)=O MXMXXUIOCREOTJ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108010073361 BioXtra Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010061182 Genitourinary tract infection Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 101710184548 Phosphoenolpyruvate transferase Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004189 ion pair high performance liquid chromatography Methods 0.000 description 1
- 238000004249 ion pair reversed phase high performance liquid chromatography Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000003953 normal phase liquid chromatography Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/84—Preparation of the fraction to be distributed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/30—Partition chromatography
- B01D15/305—Hydrophilic interaction chromatography [HILIC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65502—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a three-membered ring
- C07F9/65505—Phosphonic acids containing oxirane groups; esters thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/64—Electrical detectors
- G01N2030/645—Electrical detectors electrical conductivity detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/84—Preparation of the fraction to be distributed
- G01N2030/8447—Nebulising, aerosol formation or ionisation
- G01N2030/8452—Generation of electrically charged aerosols or ions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/64—Electrical detectors
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
Claims (15)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201930256A ES2784076B2 (es) | 2019-03-21 | 2019-03-21 | Metodo para la deteccion y cuantificacion de fosfomicina y de sus impurezas y/o productos de degradacion |
PCT/EP2020/056327 WO2020187644A1 (en) | 2019-03-21 | 2020-03-10 | Method for the detection and quantification of fosmomycin, impurities and degradation products thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
ES2872674A2 ES2872674A2 (es) | 2021-11-02 |
ES2872674R1 ES2872674R1 (es) | 2022-07-21 |
ES2872674B2 true ES2872674B2 (es) | 2023-06-29 |
Family
ID=69810825
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201930256A Active ES2784076B2 (es) | 2019-03-21 | 2019-03-21 | Metodo para la deteccion y cuantificacion de fosfomicina y de sus impurezas y/o productos de degradacion |
ES202190053A Active ES2872674B2 (es) | 2019-03-21 | 2020-03-10 | Metodo para la deteccion y cuantificacion de fosfomicina y de sus impurezas y/o productos de degradacion |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201930256A Active ES2784076B2 (es) | 2019-03-21 | 2019-03-21 | Metodo para la deteccion y cuantificacion de fosfomicina y de sus impurezas y/o productos de degradacion |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220146470A1 (es) |
CA (1) | CA3132408A1 (es) |
ES (2) | ES2784076B2 (es) |
MX (1) | MX2021011401A (es) |
WO (1) | WO2020187644A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102353452B1 (ko) * | 2020-12-23 | 2022-01-21 | 한국과학기술원 | 에어로졸화된 비말 검출장치 |
CN113406259A (zh) * | 2021-05-28 | 2021-09-17 | 海南海灵化学制药有限公司 | 一种拉氧头孢钠杂质的检测方法 |
CN115097051B (zh) * | 2022-07-27 | 2023-03-24 | 广州艾奇西新药研究有限公司 | 一种使用高效液相色谱分离检测磷霉素钠及其制剂中有关物质的方法 |
CN115798573B (zh) * | 2023-02-02 | 2023-05-09 | 武汉宏韧生物医药股份有限公司 | 一种药物成分分析方法及装置 |
CN117213385A (zh) * | 2023-10-10 | 2023-12-12 | 江苏神力特生物科技股份有限公司 | 一种检测和定量牛樟芝固态发酵物中的安卓奎诺尔的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9441053B2 (en) * | 2013-07-11 | 2016-09-13 | Scinopharm Taiwan, Ltd. | Analytical method for detecting sulfated oligosaccharides |
GB201417341D0 (en) * | 2014-10-01 | 2014-11-12 | Isis Innovation | Chromatography |
-
2019
- 2019-03-21 ES ES201930256A patent/ES2784076B2/es active Active
-
2020
- 2020-03-10 MX MX2021011401A patent/MX2021011401A/es unknown
- 2020-03-10 ES ES202190053A patent/ES2872674B2/es active Active
- 2020-03-10 CA CA3132408A patent/CA3132408A1/en active Pending
- 2020-03-10 US US17/441,551 patent/US20220146470A1/en active Pending
- 2020-03-10 WO PCT/EP2020/056327 patent/WO2020187644A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20220146470A1 (en) | 2022-05-12 |
ES2784076A1 (es) | 2020-09-21 |
ES2872674R1 (es) | 2022-07-21 |
MX2021011401A (es) | 2022-02-11 |
ES2784076B2 (es) | 2021-04-12 |
CA3132408A1 (en) | 2020-09-24 |
ES2872674A2 (es) | 2021-11-02 |
WO2020187644A1 (en) | 2020-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2872674B2 (es) | Metodo para la deteccion y cuantificacion de fosfomicina y de sus impurezas y/o productos de degradacion | |
Armstrong et al. | Simultaneous UHPLC-UV analysis of hydroxychloroquine, minocycline and doxycycline from serum samples for the therapeutic drug monitoring of Q fever and Whipple’s disease | |
Trivedi et al. | A rapid, stability-indicating RP-HPLC method for the simultaneous determination of formoterol fumarate, tiotropium bromide, and ciclesonide in a pulmonary drug product | |
Ye et al. | Quantification and pharmacokinetics of alpinetin in rat plasma by UHPLC–MS/MS using protein precipitation coupled with dilution approach to eliminate matrix effects | |
Santini et al. | Development of a high performance liquid chromatography method for the determination of tedizolid in human plasma, human serum, saline and mouse plasma | |
Acharjya et al. | Development of a high-performance liquid chromatographic method for determination of letrozole in wistar rat serum and its application in pharmacokinetic studies | |
Seo et al. | Rapid determination of sumatriptan in human plasma by ultra performance liquid chromatography–tandem mass spectrometry and its application to clinical pharmacokinetic study | |
CN110031568B (zh) | 一种测定人血浆中沙库巴曲、去乙基沙库巴曲和缬沙坦浓度的方法 | |
Jeong et al. | A sensitive UPLC–ESI–MS/MS method for the quantification of cinnamic acid in vivo and in vitro: Application to pharmacokinetic and protein binding study in human plasma | |
Bleyzac et al. | Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma | |
Quernin et al. | Quantification of busulfan in plasma by liquid chromatography–ion spray mass spectrometry: application to pharmacokinetic studies in children | |
Lago et al. | Capillary zone electrophoresis method to assay tipranavir capsules and identification of oxidation product and organic impurity by quadrupole-time of flight mass spectrometry | |
Ye et al. | Structural characterization of low level degradants in aztreonam injection and an innovative approach to aid HPLC method validation | |
Naik et al. | RP-HPLC Method for the Estimation of 6-Mercaptopurine in spiked human plasma and pharmaceutical formulations | |
ES2865261T3 (es) | Procedimientos para el análisis y resolución de preparaciones de dianhidrogalactitol y derivados o análogos de los mismos | |
Xiong et al. | Determining concentrations of icotinib in plasma of rat by UPLC method with ultraviolet detection: Applications for pharmacokinetic studies | |
El-Kimary et al. | High-performance thin-layer chromatographic assay of metformin in urine using ion-pair solid-phase extraction: Application for bioavailability and bioequivalence study of new microbeads controlled release formulation | |
Vaja et al. | Development and Validation of RP-HPLC Method for Estimation of Lurasidone and its impurities Lurasidone 1 and Lurasidone 8 | |
Amelin et al. | Simultaneous LC-MS identification and determination of active ingredients in septolete, calgel, and novosept forte preparations | |
Zhang et al. | Determination of cycloserine in microdialysis samples using liquid chromatography–tandem mass spectrometry with benzoyl chloride derivatization | |
WO2020081599A1 (en) | Separation of vancomycin and its degradation products | |
Gholizadeh-Hashjin et al. | Compatibility study of formoterol fumarate-lactose dry powder inhalation formulations: Spray drying, physical mixture and commercial DPIs | |
Abdessadek et al. | Simple HPLC-UV method for determination of metformin in human plasma and erythrocytes application to therapeutic drug monitoring | |
Jain et al. | Development and validation of an HPTLC method for determination of minocycline in human plasma | |
Tekkeli et al. | A new HPLC method with fluorescence detection for the determination of memantine in human plasma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BA2A | Patent application published |
Ref document number: 2872674 Country of ref document: ES Kind code of ref document: A2 Effective date: 20211102 |
|
EC2A | Search report published |
Ref document number: 2872674 Country of ref document: ES Kind code of ref document: R1 Effective date: 20220714 |
|
FG2A | Definitive protection |
Ref document number: 2872674 Country of ref document: ES Kind code of ref document: B2 Effective date: 20230629 |